ELTX - CIK 0001601485
Elicio Therapeutics, Inc. (ELTX) reported net income of -$39.57M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$39.57M | +23.8% |
| FY 2024 | -$51.90M | -47.5% |
| FY 2023 | -$35.20M | -24.8% |
| FY 2022 | -$28.21M | +48.3% |
| FY 2021 | -$54.57M | +31.9% |
| FY 2020 | -$80.11M | - |
Elicio Therapeutics, Inc. (ELTX) reported net income of -$39.57M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Elicio Therapeutics, Inc.'s net income grew from -$80.11M to -$39.57M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.